Strategic Alternatives Review 2026: 10 Options, Timeline, Leaks

A strategic alternatives review is a board-led process that tests whether a sale, merger, recapitalization, minority investment, carve-out, spin-off, partnership, restructuring or wind-down would create more value than the current plan, with the status quo always a live answer. "Exploring strategic alternatives" in a press release means that review has started, not that a deal exists. Historically about a third of public announcers were sold within a year, so most reviews end some other way. The process usually takes four to six months to a signed deal and about eight months to close, and the biggest avoidable risk along the way is a leak.

Key takeaways

• It is a test, not a sale. In Jenny Zha Giedt's study of more than 1,200 US announcements from 1990 to 2018, 41% drew an M&A offer within a year and 32% were sold (Duke FinReg Blog summary, historical data).
• Ten options, four trade-offs. Each option trades cash now, control kept, time to close and leak exposure differently. The Strategic Alternatives Decision Matrix below scores all ten.
• Timeline: about 7.9 months on average to close an M&A deal in Peony's Q3 2026 dataset of 733 transactions (State of M&A Data Rooms).
• Governance: once a sale of control is on the table, Delaware directors must seek the best price and other terms reasonably available (Revlon). Conflicts call for a special committee.
• Disclosure: US public companies usually have no duty to announce a review. "No comment" is generally treated as silence (Basic v. Levinson), and Form 8-K is triggered by signing a definitive agreement.
• Leaks: a leaked review carries the same costs as an announced one. Climb the Disclosure Ladder one rung at a time and run outreach through a data room that gives each bidder its own walled, NDA-gated, watermarked group.

I'm Deqian Jia, co-founder of Peony, a data room company used by 8,000+ customers in 60+ countries. A strategic review is one of the most delicate processes that runs through our rooms, because the board is disclosing its most sensitive material to parties that may become owners, partners, competitors or nobody at all. This guide is written for the CEO, CFO, founder, director or PE sponsor deciding whether to start a review, and for anyone who just read that a company is "exploring strategic alternatives" and wants to know what happens next.

If your company is IP-heavy and the worry is a bidder walking away with your source code or engineering secrets, read our deep dive on running a data room for strategic alternatives after this one. It covers Crown-Jewel Tiering for technical disclosure. This page covers the whole review: options, governance, disclosure, leaks and the distressed variant.

What does "exploring strategic alternatives" actually mean?

It means the board has formally opened the question of whether the company should stay on its current path, and has hired or will hire advisors to test the alternatives against that path. It is not an agreement, an auction or even a decision to sell. The status quo with a sharper plan is always one of the possible answers.

Companies use the phrase for three different situations, and the release usually tells you which one you are looking at:

1. Inbound interest. A bidder has approached the board, and the board wants to see whether others will pay more. Warner Bros. Discovery started its review on October 21, 2025 "in light of unsolicited interest the Company has received from multiple parties" (WBD release). Bioventus did the same on August 5, 2026 after "a recent unsolicited acquisition proposal and multiple other expressions of interest" (Bioventus 8-K exhibit).
2. A strategic reset. Growth has stalled, an activist is pushing, or the stock trades at a discount the board thinks a buyer would close.
3. A cash problem. Runway is short, so the list includes asset sales, licensing and an orderly wind-down. Jasper Therapeutics' June 1, 2026 release listed "an orderly wind-down of operations" alongside a sale and a merger (Jasper 8-K exhibit).

How do you decode a strategic alternatives press release?

Use the Press Release Decoder below. The percentages come from Jenny Zha Giedt's historical sample of public announcements from 1990 to 2018, as summarized on the Duke FinReg Blog.

How often does a strategic alternatives review end in a sale?

About one in three public reviews historically ended in a completed sale within a year, and about two in three did not. In Jenny Zha Giedt's study of more than 1,200 US public-company announcements from 1990 to 2018, 41% were followed by an M&A offer within 12 months and 32% by a completed sale. For comparable companies that made no announcement, the rates were 7% and 5% (Duke FinReg Blog). Treat these as historical base rates. There is no comparable public dataset for private companies, whose reviews are never announced.

The market's reaction is lopsided:

• On the day: the stock usually rises. The authors' own summary describes an average jump of more than 5% on the announcement, followed by a 9% drop over the next six months (CLS Blue Sky Blog).
• Afterwards: the peer-reviewed version, published in the Review of Accounting Studies in March 2026, opens with a blunt line: "Companies' strategic alternatives announcements lead to negative future stock returns." The authors find that "investors appear overly optimistic about a potential merger or acquisition" (Rim and Zha Giedt, 2026).
• If no deal follows: in Zha Giedt's earlier working paper (1,006 announcements, 1990 to 2014), announcers that were not acquired earned long-run returns 14 to 15 percentage points below similar peers that also stayed independent (MPRA working paper, historical data).

Reviews that end without a sale are common and not always failures. On March 18, 2026, GSI Technology said its board "has concluded the Company's previously announced review of strategic alternatives." After engaging with multiple parties, the board decided that continuing its standalone strategy was in stockholders' best interests (GSI 8-K exhibit). The lesson for a board is practical: decide before you announce whether you can live with a "no deal" outcome in public.

What are the 10 options in a strategic alternatives review?

A full review tests ten options: a sale, a merger, a recapitalization, minority growth equity, a divestiture or carve-out, a spin-off, a partnership or joint venture, a restructuring, a wind-down and the status quo. They are not mutually exclusive. Many processes run two in parallel, for example a sale against a dividend recap, or a carve-out against a spin-off, and let the bids decide.

The timelines below are typical planning ranges for a mid-market company, not statistics. The one sourced anchor is Peony's Q3 2026 dataset, where M&A deals took about 7.9 months on average to close.

Three options deserve a closer look because readers confuse them:

• Dividend recap vs sale. In a dividend recap the company borrows and pays the proceeds out to owners, who keep control. It is often the fallback when sale bids come in light, which is why bankers like to run it in parallel.
• Carve-out vs spin-off. A carve-out sells a unit to a buyer for cash. A spin-off hands the unit's shares to existing shareholders, usually tax-free if it meets Section 355, so no cash comes in. Our guides to spin-offs and carve-out data rooms go deeper.
• Chapter 11 vs a 363 sale. A Chapter 11 reorganization keeps the company and rewrites its debts. A sale under 11 U.S.C. Section 363 lets the debtor sell assets "other than in the ordinary course of business" after notice and a hearing, and in defined cases free and clear of liens and other interests.

Which option fits your goal? The Strategic Alternatives Decision Matrix

Score each option against the four things shareholders actually trade: cash now, control kept, time to close and leak exposure. Then pick the option whose profile matches the owners' goal, not the one the banker knows best. I call this the Strategic Alternatives Decision Matrix. It is the first exhibit I would put in front of a board that is deciding whether to start a review at all.

How to use the matrix in a board meeting:

1. Write the shareholder goal in one sentence first. "Full liquidity for the founders within 12 months" points to a sale. "Fund expansion without losing control" points to growth equity or a recap.
2. Strike any option whose leak exposure the business cannot survive. A company with key-customer concentration may not survive a broad auction that leaks, which favors a targeted process with fewer bidders.
3. Keep two options alive. The strongest negotiating position in a review is a credible second path, such as a recap that the sale bids must beat.

How does a strategic alternatives review run, step by step?

A sale-led review runs through seven stages: board authorization, preparation, outreach under NDA, a first round, a second round with full diligence, signing and closing. That takes about four to six months to signing and about eight months to close. Peony's State of M&A Data Rooms (Q3 2026 edition, 733 transactions from $1M to $500M) puts the average time to close at about 7.9 months, with a median of 5.5 bidders per room.

A real 2026 timeline shows how this plays out. The preliminary merger proxy of The Baldwin Insurance Group, a Tampa-based insurance brokerage, sets out its process (Baldwin PREM14A):

• April 23, 2026: the board directed its banker, Ardea, "to continue to further explore strategic alternatives."
• May 20: the board authorized outreach.
• June 20: 24 financial investors received access to a virtual data room. Ardea had contacted 25, and 24 signed NDAs "which contained customary 'standstill' provisions."
• July 23: the board formed a special committee of independent and disinterested directors.
• July 27 and September 1: first-round bids, then final proposals.
• September 14: merger agreement at $32.50 per share in cash, about an 87.5% premium to the unaffected June 17 close.

That is under five months from board direction to signing. Closing is expected in the first quarter of 2027, according to the Business Observer, which puts the deal at about $7.7 billion including debt. For the step-by-step mechanics of a sell-side process, see our M&A process guide and how to write a CIM.

What are the board's duties in a strategic alternatives review?

Directors owe their normal duties of care and loyalty throughout. Once a deal would pass control to a third party, Delaware's Revlon standard applies: directors must seek the best price and other terms reasonably available, and a court will look harder at how they got there. In the 1986 Revlon decision, the Delaware Supreme Court said that once a sale became inevitable, "the directors' role changed from defenders of the corporate bastion to auctioneers charged with getting the best price for the stockholders at a sale of the company" (Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., 506 A.2d 173, 182).

Current practice, as Faegre Drinker summarized it in a guide updated in June 2026 (Faegre Drinker):

• Trigger: "Revlon duties apply to transactions that will cause control of a company to pass to a third party." The guide lists "a sale or merger for cash or debt securities" as a trigger, while a merger of equals or a common-stock merger with a widely held public company is not.
• Standard: "Directors are simply charged with selecting the best price and other terms reasonably available under the circumstances." They are not required to find a hypothetical ideal deal.
• No mandatory auction: "Revlon duties may be satisfied through a negotiation with a single counterparty," provided the board is reasonably informed, often through a market check.
• Conflicts: where there are material conflicts of interest, "a special committee of disinterested directors should act" so that interested people do not negotiate or approve the deal.

In practice that means four governance artifacts: board minutes that show the alternatives considered (including the status quo), a committee charter if there are conflicts, a fairness opinion from a financial advisor, and a clean record of who saw what and when. That last record lives in your data room. Private companies outside Delaware, or with a controlling owner, face different standards, so take advice from counsel in your state of incorporation.

Who should you hire for a strategic alternatives review, and what does it cost?

Hire a sell-side M&A banker with closed deals in your sector and size range, plus experienced deal counsel. Add a restructuring adviser if liquidity is tight and a separate committee adviser if there is a conflict. Fees are mostly contingent on a deal closing, with a retainer up front. The sector decides more than the brand name on the banker's door, because buyers, regulators and valuation drivers differ by industry.

What it costs. For a mid-market sale, expect a monthly retainer that is usually credited against a success fee of roughly 2% to 10% of deal value, falling as deal size grows. Our M&A advisor fees guide has the worksheet for $5M to $100M deals. At the large end, Baldwin's proxy shows how the two adviser roles are paid differently (Baldwin PREM14A):

• The company's banker, Ardea: $76.3 million, "the principal portion of which is payable contingent upon the consummation of the Mergers."
• The special committee's adviser, Perella Weinberg: $1.0 million on engagement, $7.5 million on delivering its opinion and up to $2.5 million at the committee's discretion at closing.

The split is deliberate. The adviser who checks the price for the independent directors is paid mostly whether or not the deal closes, so its opinion does not depend on the deal happening.

Should a public company announce the review or stay quiet?

Most US public companies have no legal duty to announce a review, so the choice is strategic. Announce when you want to flush out bidders or must respond to a leak. Stay quiet when a public "for sale" sign would hurt customers, employees or leverage. The rules that frame the choice:

• No general duty to disclose. In Basic Inc. v. Levinson (1988), the Supreme Court wrote: "Silence, absent a duty to disclose, is not misleading under Rule 10b-5. 'No comment' statements are generally the functional equivalent of silence" (opinion, footnote 17). The same footnote cites the NYSE's position that a premature announcement may be delayed for a valid business purpose where adequate security can be maintained.
• Form 8-K comes at signing, not at the start. Item 1.01 requires disclosure when a company enters a material definitive agreement, and a report is generally due "within four business days after occurrence of the event" (SEC Form 8-K). Starting a review is not an 8-K event.
• Regulation FD covers bidders under NDA. Reg FD bans selective disclosure of material nonpublic information to market professionals and some holders. It exempts disclosure "to a person who expressly agrees to maintain the disclosed information in confidence," and to advisers who owe a duty of confidence, such as an investment banker (17 CFR 243.100). That is why every bidder signs an NDA before it sees anything.
• Exchange rules bite when it leaks. Nasdaq's IM-5250-1 lets a company hold back material events "where it is possible to maintain confidentiality of those events and immediate public disclosure would prejudice the ability of the Company to pursue its legitimate corporate objectives." But if rumors or unusual trading suggest the news is out, "a clear public announcement may be required as to the state of negotiations" (Nasdaq rule text, SEC filing). NYSE Section 202.05 sets the same baseline: release quickly any news that might reasonably be expected to materially affect the market for the company's securities.
• Other triggers. A company buying back its own stock, an executive's misleading denial or a prior statement that is now wrong can each create a duty to speak. Counsel should clear any comment.

If you do announce, the market has settled on standard language. Recent examples:

• Warner Bros. Discovery (October 21, 2025): "There is no deadline or definitive timetable set for completion of the strategic alternatives review process," and it "does not intend to make any further announcements regarding the review" unless the board approves a specific transaction or decides further disclosure is appropriate (WBD release).
• Bioventus (August 5, 2026): "The Company has not set a timetable for the completion of strategic alternatives review process," and "there can be no assurance that the Company's review will result in any transaction or other strategic outcome" (Bioventus 8-K exhibit).
• Jasper Therapeutics (June 1, 2026): "Jasper does not intend to discuss or disclose further developments during this process" unless its board approves a specific action or disclosure is required (Jasper 8-K exhibit).

Private companies have no public-disclosure duty at all. Their confidentiality rests entirely on NDAs, a tight internal circle and the controls in their data room.

The Disclosure Ladder: who knows what, rung by rung

Move up one rung only when the next rung earns you something, because each rung multiplies the number of people who can leak. I call this the Disclosure Ladder.

What does a leak cost, and how do you stop one?

A leak forces the company into the costs of an announcement it did not choose: a pressured share price, unsettled customers and employees, and a public "no deal" if the review fails. Zha Giedt's working paper tested this directly. Comparing 151 media leaks of strategic reviews with voluntary announcements, it found that "firms that experience media leaks of their strategic reviews experience similar valuation costs and benefits" (MPRA working paper, historical data, 1990 to 2014). The same paper found abnormally lower revenues, operating income and employee growth after a review becomes public. It attributes this to the public admission of business problems "alienating stakeholders such as customers and employees."

A leak also moves the price that bids are judged against. Baldwin's proxy measures its premium from the "unaffected" close on June 17, 2026. The Business Observer describes that date as the day before news surfaced that the company was looking at a take-private. Once the market prices in a deal, every later bid is compared with a higher, rumor-inflated price.

Staged disclosure is how deal teams contain the risk:

• NDA with standstill and non-solicit. The NDA keeps the information confidential and brings bidders within Reg FD's exemption. The standstill stops a bidder from buying shares or going hostile. The non-solicit protects your people. Baldwin's 24 NDAs all carried standstill provisions.
• Clean team. Competitively sensitive data, such as customer-level pricing or margins, goes only to a small group of the bidder's outside advisers and non-operating staff, to manage antitrust and misuse risk. See our clean team data room guide.
• Tiered access. Teaser and summary data at NDA, full diligence only for the shortlist, crown jewels only near signing.

Peony is the data room layer for a confidential strategic review

Peony gives each bidder its own NDA-gated, watermarked group inside one room, shows page by page who is reading what, and lets you cut a bidder off in one change, for $52 per admin per month on the Data Room plan. That covers the parts of the Disclosure Ladder that software can control. Here is how each feature maps to the job:

• Visitor groups per bidder. Each strategic, sponsor or lender gets its own group with its own folder permissions and security settings, so each sees only the subset you open to it, and an on/off toggle arms or kills one audience without touching the others. Because the NDA gate is set per group, strategics, lenders and sponsors can each sign a different agreement in the same room (visitor groups).
• A signed NDA gate. Viewers sign before any file opens, and Peony records the signature, timestamp and IP address. In Peony's Q3 2026 dataset, 62% of rooms used an NDA gate (NDA gating).
• Dynamic watermarks. Each viewer's email, IP and timestamp are rendered onto every page server-side, so a leaked page traces back to a person (watermarks).
• Screenshot protection. Basic blocking on supported desktop browsers on Business. Screenshield on Data Room extends it to iPhone, iPad and Android (screenshot protection).
• Page-level analytics. Every plan shows which pages each viewer opened and how long they spent on each page, so you can tell the bidder working through the customer contracts from the one that opened the teaser once (page analytics).
• One-change cut-off when a party drops. Set a folder to No access for one group, remove one person, or switch a whole group off. The change applies on the viewer's next load (revoke access).

The numbers that matter for budgeting: Peony's Data Room plan is $52 per admin per month billed yearly ($75 monthly), with unlimited rooms, documents and storage, and viewers are free and unlimited on every plan. Business is $30 ($44) with three rooms per admin, a simple NDA and screenshot protection, but no per-bidder groups. Deal Team is $64 ($89), with a minimum of four admins, and adds advanced Q&A routing and redaction. In our Q3 2026 data, sub-$50M rooms averaged $219 a month, the median room hosted 5.5 bidders, and the median time from sign-up to first uploaded document was 4 minutes 19 seconds. Start now.

Honest limits. For a $500M-plus auction where the bank or the counterparties standardize on Datasite or Intralinks, use what they expect. Datasite averages about $68,000 a year per contract, according to Vendr, and large banks pay for that integration deliberately. No data room replaces your banker or counsel. Watermarks deter and trace leaks, but they cannot stop someone photographing a screen with a second phone.

Which recent strategic reviews show how these end?

The 2025 to 2026 record covers every ending: a contested sale, a negotiated sale, a quiet take-private, a decision to stay independent and a court-run sale. All facts below come from the companies' own releases, SEC filings or named reporting.

Bioventus (August 2026) had an open review at the time of writing. Jasper Therapeutics' June 2026 review ended on July 16, 2026, when it completed an all-stock acquisition of Kira Pharmaceuticals alongside a private placement of about $132 million (Jasper release).

What if the company is facing financial challenges?

When liquidity is the problem, a strategic review becomes a race against the cash runway. The options narrow to rescue capital, a sale of the company or units, an out-of-court restructuring, Chapter 11, a 363 sale or an orderly wind-down. The order in which you can still choose them depends on how many weeks of cash you have, so the first deliverable is a 13-week cash-flow forecast, not a CIM.

Distress is common right now. Epiq AACER counted 6,560 commercial Chapter 11 filings from January 1 to September 30, 2026, an 11% increase from 5,895 in the same period of 2025 (ABF Journal).

Three practical points from the distressed track:

• Equity often gets nothing. In a 363 sale, proceeds go to creditors in priority order, and shareholders are last in line.
• People rules still apply. Under the federal WARN Act, an employer covered by the Act "shall not order a plant closing or mass layoff until the end of a 60-day period" after written notice (29 U.S.C. 2102), so a wind-down plan needs that clock in it.
• The data room must open in days, not weeks. Lenders, a stalking-horse bidder and later bidders all need separate access at once, often with different NDAs. In Peony's Q3 2026 data, the median room took 12.6 days from first opening to its first outside viewer; a distressed process usually needs that compressed.

For healthcare companies, licenses, payer contracts and patient records complicate any transfer, so bring in healthcare regulatory counsel early. Our restructuring data room hub explains strategic versus distressed tracks, the distressed asset sale guide covers the 363 room, what happens when a company is liquidated covers the end state, and the restructuring solution page shows how Peony is set up for lender and bidder groups.

What should a board do in the first 30 days of a review?

Settle the goal, the governance and the confidentiality plan before anyone outside the company hears about it. The 30-Day Review Kickoff Checklist I'd use:

1. Write the shareholder goal in one sentence and run the ten options through the Decision Matrix.
2. Run a conflicts check on management, large holders and directors, and form a special committee if anyone could be on the buy side.
3. Interview two or three bankers with sector deals in your size range. Negotiate a creditable retainer and a tail limited to named buyers (fees guide).
4. Decide your rung on the Disclosure Ladder and write the no-comment script before you need it.
5. Build the data room index and tiers, with one group per bidder, a signed NDA gate and watermarks on, before the first teaser goes out (multi-bidder room guide).
6. If cash is tight, commission the 13-week cash-flow forecast and a liquidation analysis in week one.
7. Set the decision rule for ending the review without a deal, and the message you will use if that happens.

FAQ

What does it mean when a company is exploring strategic alternatives?

It means the board has formally started testing whether another path beats the current plan: a sale of the whole company, a merger, a recapitalization, minority equity, selling or spinning off a unit, a partnership, a restructuring or a wind-down, with the status quo always on the list. It is not a commitment to sell. When a public company announces a review, it usually signals inbound interest or an invitation to bidders, and most companies say they will not comment again until the board approves a specific transaction.

How often does a strategic alternatives review end in a sale?

Historically, about a third of public announcements ended in a completed sale within a year. In Jenny Zha Giedt's study of more than 1,200 US announcements from 1990 to 2018, 41% were followed by an M&A offer within 12 months and 32% by a completed sale, against 7% and 5% for comparable companies that announced nothing. So roughly two in three announcers had not sold a year later. Reviews also end in recapitalizations, unit sales, restructurings or a decision to stay standalone, as GSI Technology announced in March 2026.

Is it good or bad for the stock when a company announces it is exploring strategic alternatives?

Good on the day, often bad afterwards. The share price has historically jumped by more than 5% on the announcement, but a 2026 Review of Accounting Studies paper by Hyun Jung Rim and Jenny Zha Giedt finds that these announcements lead to negative future returns, because investors appear overly optimistic about a takeover and underweight the weak fundamentals that prompted the review. Companies that go on to be acquired usually capture a premium; companies whose review ends without a deal have historically lagged their peers.

What are the options in a strategic alternatives review?

Boards usually test ten: a sale of the company, a merger, a recapitalization or dividend recap, minority growth equity, a divestiture or carve-out of a unit, a spin-off, a strategic partnership or joint venture, a restructuring (out-of-court, Chapter 11 or a Section 363 sale), a wind-down or liquidation, and the status quo with a sharper plan. They differ on four things shareholders care about most: how much cash they deliver now, how much control owners keep, how long they take to close and how many outsiders see sensitive data.

We own a profitable founder-led company: should we sell, do a dividend recap or take minority growth equity?

Pick by what the owners want from the next five years. A full sale fits if the goal is maximum liquidity now and a buyer will pay a control premium; plan on roughly eight months to close, and your control ends. A dividend recap returns part of the value in cash, funded by new debt, while owners keep control, so it suits a business with stable cash flow that can carry leverage. Minority growth equity brings capital for expansion and some secondary liquidity, in exchange for board seats and investor protections. Many boards test two of these in parallel and let the bids decide.

How long does a strategic alternatives review take?

Plan on four to six months from board approval to a signed deal and about eight months to closing for a sale. Deals in Peony's Q3 2026 dataset of 733 M&A transactions took about 7.9 months on average to close. In 2026, The Baldwin Insurance Group's board directed its banker on April 23 to further explore alternatives and signed a take-private on September 14, with closing expected in the first quarter of 2027. Spin-offs, regulated utilities and Chapter 11 cases run on different clocks, from seven weeks for a fast 363 sale to well over a year.

Does the board need a special committee, and what are Revlon duties in a strategic review?

A special committee of independent, disinterested directors is needed when management, a large holder or a director has a conflict, such as rolling equity into a buyer. Its job is to run the review independently of the conflicted parties: it hires its own legal counsel and financial advisor, controls who talks to bidders and what they see, weighs every option including staying independent, and has the authority to reject any deal. Revlon duties apply under Delaware law when a deal will pass control of the company to a third party: directors must select the best price and other terms reasonably available, which can be met through a broad auction or a negotiation with a single counterparty backed by a market check. In 1986 the Delaware Supreme Court described directors in a sale as auctioneers charged with getting the best price for the stockholders.

What advisor should a mid-sized company hire to evaluate strategic alternatives, and what do they charge?

Hire a sell-side M&A banker with closed deals in your sector and size range, plus deal counsel, and add a restructuring adviser if liquidity is tight. Sector depth matters: an insurance brokerage should start with the insurance M&A advisors, a utility holding company with the energy and utility advisors, a healthcare company with the healthcare M&A advisors and a beauty brand with the consumer products advisors. Expect a monthly retainer plus a success fee of roughly 2% to 10% of deal value, falling as deals get bigger; see our M&A advisor fees guide.

Do public companies have to announce that they are exploring strategic alternatives?

Usually not. US securities law imposes no general duty to disclose a review or early merger talks: the Supreme Court said in Basic v. Levinson that silence, absent a duty to disclose, is not misleading, and that no comment statements are generally the functional equivalent of silence. A Form 8-K is due within four business days of signing a material definitive agreement. A duty can arise earlier if the company is trading its own shares, has made a statement that is now misleading, or the news leaks and moves the stock, when NYSE and Nasdaq rules may require a clear public statement.

How do you keep a strategic alternatives review confidential and stop leaks?

Climb the Disclosure Ladder one rung at a time: a small quiet circle, then a board committee, then a banker, then limited outreach under NDAs with standstill terms, and only then any announcement. Give each bidder its own data room group so no one sees the others, gate every group behind a signed NDA, stamp every page with a dynamic watermark naming the viewer, block screenshots and downloads, and read page-level analytics for unusual behavior. In Peony, visitor groups, the signed NDA gate and dynamic watermarks come on the Data Room plan at $52 per admin per month billed yearly, and switching off a bidder's group takes effect on that viewer's next page load.

Our healthcare company is facing financial challenges and exploring strategic alternatives: what are our options?

The list narrows to options that fix the balance sheet in time: a rescue capital raise or recapitalization, a sale of the company or of non-core units, an out-of-court restructuring with lenders, a Chapter 11 reorganization, a Section 363 sale of assets with court approval, or an orderly wind-down. Build a 13-week cash-flow forecast first, because runway decides which options remain. Hire a restructuring adviser and healthcare counsel early, since licenses, payer contracts and patient records complicate any transfer; our healthcare M&A advisors guide and restructuring data room hub cover both tracks.

What data room do you need for a strategic alternatives review, and what does it cost?

You need a room that walls bidders off from each other, gates access behind a signed NDA, traces leaks to a named viewer and shows which bidders are actually reading. Peony covers that on its Data Room plan at $52 per admin per month billed yearly ($75 monthly), with unlimited rooms and storage and free, unlimited viewers. Business at $30 includes screenshot protection and a simple NDA but not per-bidder groups, and Deal Team at $64 (minimum four admins) adds advanced Q&A and redaction. Datasite averages about $68,000 a year per contract, according to Vendr, and suits deals above $500M where counterparties expect it.

Related Resources

• Data Room for Strategic Alternatives: the IP-heavy deep dive, with Crown-Jewel Tiering for source code and engineering secrets
• M&A Advisor Fees: success fees, retainers and tails on $5M to $100M deals
• Best M&A Advisors: advisor guides for 49 cities and 24 sectors
• State of M&A Data Rooms: our dataset of 733 M&A transactions, including time to close and bidders per room
• Data Room for Restructuring: strategic versus distressed tracks, and how the room changes when lenders arrive
• Distressed Asset Sale Data Room: running a fast, defensible 363 sale room
• Clean Team Data Room: sharing competitively sensitive data with a rival bidder
• Carve-Out Data Room Guide: sale perimeter, transition services and Day-1 separation
• What Is a Spin-Off?: tax rules and how a spin-off differs from a carve-out
• Best Data Room for Multiple Bidders: one room, a separate wall for each bidder

Running a review and need bidders walled off from each other by next week? Start now.

---

About the author: Deqian Jia is the co-founder of Peony, the data room platform used by 8,000+ customers in 60+ countries for M&A, fundraising and restructuring. Peony is SOC 2 Type II-ready and ISO 27001-ready, with both audits underway.